ClinicalTrials.gg
RecruitingNCT07669298T-REXUpdated Jun 25, 2026

Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer

An interventional study of Active surveillance and Adjuvant chemoradiotherapy in Rectal Cancer, sponsored by Medical University of Gdansk. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Medical University of Gdansk · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Rectal Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 3 of them phase 3. Rectal Neoplasms · Poland.

Planned enrollment
10th of 27
480 · median 260
Started
2026
with 1 other
No phase
7 of 31
1 open now
Registered
30th of 31
by date

Among the 31 studies in Rectal Neoplasms with a site in Poland, this one is the 10th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 30th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 31 studies in Rectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Rectal Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if close follow-up alone (active surveillance) works as well as radiation combined with chemotherapy (chemoradiotherapy) after removing early rectal cancer in adults. The main questions it aims to answer are:

  1. Does active surveillance cause fewer serious adverse events than chemoradiotherapy within 3 years? Serious adverse events include a permanent or temporary ostomy (a surgical opening in the belly to pass stool), major bowel problems, or severe treatment-related complications.
  2. Is active surveillance as safe as chemoradiotherapy in preventing cancer from coming back or spreading within 3 years?

Researchers will compare active surveillance to chemoradiotherapy to see if surveillance causes fewer serious adverse events while keeping cancer outcomes comparable.

To join this study, participants must be adults who had an early-stage rectal cancer (T1) removed by an endoscopic procedure, and whose removed tumor showed certain features that raise the risk of cancer cells remaining nearby.

Participants will be randomly placed in one of two groups:

  1. Active surveillance group: Participants will have regular checkups, blood tests, flexible camera exams of the bowel (rectoscopy), scans of the pelvis and abdomen, and colonoscopy on a set schedule for 5 years. If cancer comes back, doctors will propose further treatment options.
  2. Chemoradiotherapy group: Participants will receive radiation to the pelvis along with a chemotherapy pill (capecitabine) or an intravenous (IV) chemotherapy drug (5-FU) for about 5 weeks. After treatment, they will have regular checkups and scans for 5 years.
Read the detailed description

The current standard treatment for T1 rectal cancer (T1N0M0) is local excision by endoscopic submucosal dissection (ESD) or intermuscular dissection (IMD) performed endoscopically or via transanal minimally invasive surgery (TAMIS). More than half of the patients treated with ESD or IMD require secondary treatment due to unfavourable histopathological features in the resected specimen. Lesions can be classified as intermediate-risk if the specimen presents at least one of the following features: poor differentiation (grade 3), lymphovascular invasion, high-grade tumour budding (grade 2-3), or deep submucosal invasion (sm2-sm3).

Secondary treatment can be performed either by total mesorectal excision (TME) or adjuvant chemoradiotherapy. The latest evidence suggests that chemoradiotherapy may offer a superior risk-benefit ratio compared to completion TME. Still, chemoradiotherapy remains associated with a substantial risk of major low anterior resection syndrome (LARS); the risk is reduced but still reported at approximately 25-33%. Given a 15-20% risk of lymph node involvement in the intermediate-risk group, chemoradiotherapy might be overtreatment for the majority of these patients. Active surveillance can reduce treatment-related morbidity, but it is associated with higher local recurrence rates. Available cohort data suggest that most recurrences are detected early during structured surveillance and are salvageable with curative-intent surgery, resulting in oncological outcomes similar to those achieved with adjuvant chemoradiotherapy. However, no randomised trial has directly compared these two strategies in this population.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • early rectal cancer
  • local excision
  • active surveillance
  • adjuvant chemoradiotherapy
  • organ preservation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed rectal cancer located extraperitoneally.
  2. Complete tumour resection (R0) by means of ESD or IMD (endoscopic or TAMIS).
  3. Pathological report indicative of:

    - pT1 with at least 1 of the following features: poor histological differentiation (grade 3), vascular invasion, lymphatic invasion, high tumour budding (grade 2-3), sm2 or sm3 invasion.

  4. Endoscopic images or video of the tumour before local excision.
  5. Maximum cancer diameter ≤ 30 mm based on the pathological assessment.
  6. cN0 stage based on pelvic MRI; lymph nodes smaller than 10 mm will be considered as benign, independent of morphologic features. Staging must be performed within 6 weeks before randomisation.

    - If enlarged lymph nodes are present on MRI performed after ESD/IMD (raising the possibility of reactive inflammatory change), fine needle aspiration (FNA) will be undertaken, and patients with negative FNA cytology will remain eligible.

  7. Adequate distant staging (thoracic and abdominal CT) without signs of distant (cM0).
  8. Have undergone a high-quality full colonoscopy:

    • Boston Bowel Preparation Scale score equal or greater than 2 in all colonic segments.
    • Documented caecal intubation.
    • All polyps ≥20 mm in diameter other than the index lesion must be completely removed and assessed pathologically.
  9. Expected survival time of more than 12 months from randomisation.
  10. At least 18 years old at the time of .
  11. performance status (ECOG PS) 0, 1 or 2.
  12. Adequate hematologic function, based upon meeting the following laboratory criteria within 7 days before randomisation:

    • (ANC) ≥ 1.5 × 10\^9/L.
    • (Hb) ≥ 8.0 g/dL (red blood cell transfusions are allowed to reach the target level).
    • count ≥ 75 × 10\^9/L.
  13. Adequate liver function, based upon meeting the following criteria within 7 days before randomisation:

    • Serum albumin ≥ 3.0 g/dL.
    • Total (in serum) ≤ 2.0 mg/dL.
    • (AST) ≤ 3 × the (ULN).
    • Alanine aminotransferase (ALT) ≤ 3× ULN.
    • Alkaline phosphatase (ALP) ≤ 3 × ULN.
  14. Adequate coagulation defined by (INR) ≤ 2.0 within 7 days before randomisation.
  15. Adequate renal function, based upon meeting the following laboratory criteria within 7 days before randomisation:

    • Serum ≥ 50 mL/min calculated using the Cockcroft-Gault formula.
    • Absence of significant proteinuria. If the subject is found to have dipstick test indicative of proteinuria equal or larger than 2+, or lab urinalysis for protein is greater than or equal to 1 g/L, the subject must demonstrate urine protein \< 1 g/24 h to be eligible.
  16. Recovery from prior treatment-related toxicities to \< Grade 2 severity per v6.0, unless the adverse events are clinically nonsignificant and/or stable on supportive therapy.
  17. Sexually active fertile subjects and their partners must agree to use medically accepted methods of (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study treatment. This does not apply to women (amenorrhoeic for at least 12 consecutive months), women aged above 55, or surgically sterilized patients (men and women).
  18. Female participants of must not be lactating or pregnant, with a negative beta-human chorionic gonadotropin (beta-hCG) test (blood or urine) at screening and before the first dose of the study treatment.

    Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, except for those who had prior hysterectomy). However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antioestrogens, ovarian suppression, low body weight, or other reasons.

  19. Written informed consent to participate in the study provided before randomisation.
  20. Capability of understanding and complying with the protocol requirements.
  21. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  22. Eligibility for thoracic, abdominal and pelvic CT and MRI.

Exclusion criteria

Exclusion Criteria:

  1. Suspicion of distant on computed tomography of the abdomen or thorax or lymph node involvement (lymph nodes >9mm in short axis); In case of isolated enlarged nodes will be required before exclusion.
  2. Mesorectal tumour involvement on pelvic MRI.
  3. Synchronous colorectal cancer in screening colonoscopy.
  4. Known genetic cancer syndrome, including, but not limited to adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome.
  5. Known inflammatory bowel disease.
  6. Previously identified allergy or to 5-FU or capecitabine.
  7. Known or suspected dihydropyridine dehydrogenase (DPD) deficiency.
  8. Prior receipt of pelvic radiation.
  9. Other to pelvic irradiation.
  10. Serious illness other than cancer that would preclude safe participation in the study
  11. Uncontrolled and significant condition, including, but not limited to, the following conditions:

    • Heart failure II or above.
    • Major cardiac arrhythmia.
    • Myocardial infarction within 6 months before randomisation.
    • Unstable angina pectoris.
    • Stroke (including , TIA) within 6 months before randomisation.
    • Thromboembolism within 3 months before randomisation.
    • History of hypertensive crisis.
  12. Gastrointestinal disorders associated with a high risk of perforation or fistula formation.
  13. Gastrointestinal bleeding event within 28 days of randomisation.
  14. Major surgery performed within 4 weeks prior to randomisation or scheduled for surgery during the study period. Complete healing from major surgery must have occurred 1 month before randomisation. Complete healing from minor surgery must have occurred at least 7 days before randomisation.
  15. Serious non-healing wound or bone fracture.
  16. Malabsorption syndrome.
  17. Pregnancy or lactation.
  18. Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Active surveillance

    Other: Active surveillance

  • Active comparator
    Adjuvant chemoradiotherapy

    Radiation: Adjuvant chemoradiotherapy

Interventions

  • OtherActive surveillance

    Active surveillance includes physical examination, and carcinoembryonic antigen (CEA) testing every 3 months during years 1-2 and every 6 months during years 3-5. Rectoscopy is performed every 3 months during years 1-2 and every 6 months during years 3-5. Pelvic MRI is performed every 6 months for 5 years. Thoracic and abdominal CT scans are performed annually for 5 years. Colonoscopy is performed at 1 year after local excision and subsequently according to findings. Recurrences are managed according to multidisciplinary team recommendations.

  • RadiationAdjuvant chemoradiotherapy

    Adjuvant long-course pelvic chemoradiotherapy will be initiated within 12 weeks after local excision. Radiotherapy consists of 45 Gy delivered in 25 fractions of 1.8 Gy once daily, 5 days per week, over approximately 5 weeks. Concurrent chemotherapy consists of either oral capecitabine 825 mg/m² twice daily on radiotherapy days or continuous intravenous 5-fluorouracil 225 mg/m²/day throughout radiotherapy. After treatment, follow-up includes history, physical examination, CEA testing, and flexible sigmoidoscopy every 6 months for 5 years; pelvic MRI every 6 months during the first 3 years; annual thoracic and abdominal CT for 5 years; pelvic CT after discontinuation of MRI surveillance; and colonoscopy at 1 year and thereafter according to findings.

06

What researchers measure

Primary outcomes

  1. Disease-related treatment failure

    Time from randomisation to the first occurrence of: 1. Cancer specific death. 2. Non-salvageable locoregional recurrence. 3. Distant metastases.

    Time frame: 3 years from randomisation

  2. Composite severe treatment-related adverse event

    Occurrence of any of the following: 1. Stoma (permanent or temporary). 2. Major LARS (score ≥30). 3. CTCAE grade ≥3 toxicity. 4. Clavien-Dindo ≥3b complications.

    Time frame: 3 years from randomisation

Secondary outcomes

  1. Disease-free survival

    Time from randomisation to first event: death (any cause), distant metastases, or locoregional recurrence

    Time frame: 3 and 5 years after randomization

  2. Overall Survival

    Time from randomization to death from any cause.

    Time frame: 3 and 5 years after randomization

  3. Stoma formation rate

    Proportion of patients with a colostomy or ileostomy (permanent or temporary) present at assessment. Stoma rates will be evaluated at predefined follow-up intervals.

    Time frame: 12 months, 3 years, and 5 years after randomization

  4. Incidence of Major Low Anterior Resection Syndrome (LARS)

    Proportion of patients with a LARS Questionnaire score of 30 points or greater, indicating major low anterior resection syndrome.

    Time frame: 12 months, 3 years, and 5 years after treatment

  5. Grade 3 or Higher Treatment-Related Toxicity

    Incidence of adverse events of grade 3 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 occurring during treatment and follow-up.

    Time frame: From treatment initiation through 12 months after completion of chemoradiotherapy.

  6. Locoregional Recurrence Rate

    Proportion of patients with radiologically or histologically confirmed recurrence within the pelvis or mesorectum.

    Time frame: 5 years after randomization.

  7. Salvageability of Locoregional Recurrence

    Proportion of detected locoregional recurrences amenable to curative-intent salvage therapy.

    Time frame: At the time of recurrence detection, up to 5 years after randomization

  8. Duration of Hospital Stay After Primary Treatment

    Total cumulative length of hospitalization following the randomized treatment strategy, measured in calendar days.

    Time frame: From the day of randomization untill 5 years from randomization.

  9. Distant Recurrence Rate

    Proportion of patients with radiologically or histologically confirmed distant metastatic disease outside the locoregional area.

    Time frame: 3 years and 5 years after randomization.

  10. Health-Related Quality of Life (EORTC QLQ-C30)

    Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).

    Time frame: Baseline, 12 months, 3 years, and 5 years after randomization

  11. Healthcare Resource Utilization Costs per Patient

    Direct healthcare resource utilization costs including treatment, procedures, imaging, hospitalization, surveillance, and management of recurrence and complications measured as a total per patient in euro (€).

    Time frame: Up to 5 years after randomization.

  12. Cost-Effectiveness

    Incremental cost-effectiveness expressed as cost per quality-adjusted life-year (QALY) gained and cost per disease-free survival year gained.

    Time frame: 3 years and 5 years after randomization

  13. Ostomy-Free Survival

    Time from randomization to permanent ostomy formation or death, with estimation of the proportion of patients alive without a permanent ostomy.

    Time frame: 3 years and 5 years after randomization.

  14. Health-Related Quality of Life (EORTC QLQ-CR29)

    Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Colorectal Cancer Module (EORTC QLQ-CR29).

    Time frame: Baseline, 12 months, 3 years, and 5 years after randomization.

07

Study locations

2 of 3 sites recruiting
  • University Hospital, Limoges
    Limoges, France
    Not yet recruiting
  • University Clinical Centre
    Gdansk, 80210, Poland
    Recruiting
    • Piotr Spychalski, MD, PhD · Contactpiotr.spychalski@gumed.edu.pl · (58) 349 20 00
    • Jaroslaw Kobiela, Prof. · Sub investigator
    • Piotr Spychalski, MD, PhD · Principal investigator
    • Piotr Wysocki, MD, PhD · Sub investigator
    • Katarzyna Polomska · Sub investigator
  • Institute of Oncology in Warsaw
    Warsaw, Poland
    Recruiting
    • Michal Kaminski, Prof. · Contactmichal.kaminski@nio.gov.pl · (22) 546 23 28
    • Michal Kaminski, Prof. · Principal investigator
    • Nastazja Pilonis, Prof. · Sub investigator
08

References and documents

Publications

  • van Oostendorp SE, Smits LJH, Vroom Y, Detering R, Heymans MW, Moons LMG, Tanis PJ, de Graaf EJR, Cunningham C, Denost Q, Kusters M, Tuynman JB. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg. 2020 Dec;107(13):1719-1730. doi: 10.1002/bjs.12040. Epub 2020 Sep 16. PubMed 32936943 ↗
  • Ouchi A, Komori K, Masahiro T, Toriyama K, Kajiwara Y, Oka S, Fukunaga Y, Hotta K, Ikematsu H, Tsukamoto S, Nagata S, Yamada K, Konno M, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Nakai K, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H; Study Group for the JSCCR-T study. How Does Omitting Additional Surgery After Local Excision Affect the Prognostic Outcome of Patients With High-risk T1 Colorectal Cancer? Ann Surg. 2024 Feb 1;279(2):290-296. doi: 10.1097/SLA.0000000000006092. Epub 2023 Sep 5. PubMed 37669045 ↗
  • Corre F, Albouys J, Tran VT, Lepilliez V, Ratone JP, Coron E, Lambin T, Rahmi G, Karsenti D, Canard JM, Chabrun E, Camus M, Wallenhorst T, Chevaux JB, Schaefer M, Gerard R, Rouquette A, Terris B, Coriat R, Jacques J, Barret M, Pioche M, Chaussade S, Cappelle E. Impact of surgery after endoscopically resected high-risk T1 colorectal cancer: results of an emulated target trial. Gastrointest Endosc. 2024 Mar;99(3):408-416.e2. doi: 10.1016/j.gie.2023.09.027. Epub 2023 Oct 2. PubMed 37793506 ↗
  • Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg. 2012 May;255(5):922-8. doi: 10.1097/SLA.0b013e31824f1c21. PubMed 22504191 ↗
  • Moolenaar LR, van Geffen EGM, Hazen SJA, Sluckin TC, Beets GL, Leijtens JWA, Talsma AK, de Wilt JHW, Tanis PJ, Kusters M, Hompes R, Tuynman JB; Dutch Snapshot Research Group; Collaborators Snapshot Registry. Salvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer - A nationwide cross-sectional cohort study. Eur J Surg Oncol. 2025 Jun;51(6):109623. doi: 10.1016/j.ejso.2025.109623. Epub 2025 Jan 23. PubMed 40009914 ↗
  • Serra-Aracil X, Pericay C, Cidoncha A, Badia-Closa J, Golda T, Kreisler E, Hernandez P, Targarona E, Borda-Arrizabalaga N, Reina A, Delgado S, Espin-Bassany E, Caro-Tarrago A, Gallego-Plazas J, Pascual M, Alvarez-Laso C, Guadalajara-Labajo H, Otero A, Biondo S; TAUTEM Collaborative Group. Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial. JAMA Surg. 2025 Jul 1;160(7):783-793. doi: 10.1001/jamasurg.2025.1398. PubMed 40434784 ↗
  • van der Schee L, Albers SC, Didden P, Lacle MM, Farina Sarasqueta A, Richir MC, Intven MPW, Tuynman JB, Hompes R, Dekker E, Vleggaar FP, Bastiaansen BAJ, Moons LMG. Results of endoscopic intermuscular dissection for deep submucosal invasive rectal cancer: a three-year follow-up study. Gut. 2025 Nov 10;74(12):1995-2003. doi: 10.1136/gutjnl-2024-334612. PubMed 40562523 ↗
  • Moolenaar LR, Ali M, Aufenacker TJ, Beets GL, Bosker RJI, Buffart TE, Burger JW, Dekker E, Denost Q, Doornebosch PG, Duijvendijk PV, Fabry HFJ, Geijsen ED, Gerhards MF, van Grevenstein WMU, Grotenhuis BA, Hoff C, Leijtens JWA, Peeters KCMJ, Pronk A, van der Schelling GP, Sietses C, Smits AB, Toorenvliet BR, van de Ven AWH, Verdaasdonk EGG, Vuylsteke RJCLM, van Westreenen HL, de Wilt JHW, Zimmerman DDE, Lange MM, van Grieken NCT, Bastiaansen BAJ, Hompes R, Marijnen CA, Dijkgraaf MGW, Moons LMG, Tanis PJ, Cunningham C, Tuynman JB; TESAR Study Group. Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2026 Jul;11(7):557-569. doi: 10.1016/S2468-1253(26)00109-3. Epub 2026 May 27. PubMed 42202843 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2037, 132 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 132 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 25, 2026
StartActual
Jun 14, 2026
Primary completionEst.
Jun 2037
CompletionEst.
Jun 2037
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07669298
Collaborators
University of Oslo, Maria Sklodowska-Curie National Research Institute of Oncology, Centre Hospitalier Universitaire Dupuytren de Limoges (CHUL), Vestre Viken Hospital Trust, Universitätsklinikum Hamburg-Eppendorf, Karolinska Institutet, University Hospital, Akershus, University of Roma La Sapienza, Hospital Clinic of Barcelona, Leuven University Medical Center, University Hospital, Ghent, Sorlandet Hospital HF, Northern Norway Regional Health Trust, Helse Stavanger HF, Haukeland University Hospital, St. Olavs Hospital
Responsible party
Michał F.Kaminski (Prof., Medical University of Gdansk) — Principal investigator
First posted
Jun 25, 2026
Start date
Jun 14, 2026
Primary completion
Jun 2037 (estimated)
Completion
Jun 2037 (estimated)
Last update
Jun 25, 2026

Study contacts

Michal Kaminski, Prof.
Contact
michal.kaminski@nio.gov.pl
(22) 546 23 28

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion